Pelion

Cardiome Pharma: More Encouraging Trial Results

>Cardiome USA is still awaiting FDA action on Kynapid however
>(almost six months overdue), and we are unsure if this could >preclude a deal in the near-term.

The IV program has a US partner with Astrellas. It has no bearing on seeking an oral partner which is a distinct program addressing a much bigger market.